Drugs for Glomerulonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 224)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Leflunomide |
Approved, Investigational |
Phase 4 |
|
75706-12-6 |
3899 |
Synonyms:
5-Methylisoxazole-4-carboxylate (4-trifluoromethyl)anilide
5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide
5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide
a,a,a-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
ARABLOC
Arabloc®|Arava®|HWA 486|HWA-486|lefunamide|SU-101
Arava
Aventis behring brand OF leflunomide
Aventis brand OF leflunomide
Aventis pharma brand OF leflunomide
Hoechst brand OF leflunomide
HWA 486
HWA-486
|
L04AA13
Leflunomida
LEFLUNOMIDE
Léflunomide
Leflunomidum
Leflunomidum [INN-Latin]
LEFUNAMIDE
LEFUNOMIDE
Lefunomide [INN-Spanish]
N-(4-Trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide
SU101
SU-101
SULOL
Α,α,α-trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide
|
|
2 |
|
Entecavir |
Approved, Investigational |
Phase 4 |
|
142217-69-4 |
153941 |
Synonyms:
ANHYDROUS ENTECAVIR
Baraclude
BMS-200475-01
Entecavir
ENTECAVIR (ANHYDROUS)
|
ENTECAVIR ANHYDROUS
ENTECAVIR HYDRATE
ENTECAVIR MONOHYDRATE
ENTECAVIRUM
SQ-34676
|
|
3 |
|
Enalaprilat |
Approved |
Phase 4 |
|
76420-72-9 |
6917719 5462501 |
Synonyms:
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
Anhydrous enalaprilat citrate
Anhydrous, enalaprilat
Biovail brand OF enalaprilat anhydrous
Boehringer ingelheim brand OF enalaprilat anhydrous
Dihydrate, enalaprilat
Enalapril acid
Enalapril diacid
Enalapril teva
ENALAPRILAT
Enalaprilat anhydrous
Enalaprilat citrate, anhydrous
Enalaprilat dihydrate
Enalaprilat, (R)-isomer, anhydrous
|
Enalaprilate
Enalaprilatum
Enalaprilic acid
Enalapril-teva
EnalaprilTEVA
Merck frosst brand OF enalaprilat anhydrous
MK-421
MK-422
MSD Brand OF enalaprilat
N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-proline
Pres IV
Teva brand OF enalaprilat
Vasotec
Xanef
|
|
4 |
|
Enalapril |
Approved, Vet_approved |
Phase 4 |
|
75847-73-3 |
40466924 5388962 5362032 |
Synonyms:
(S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylate
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
Analapril
ánalapril
Bonuten
C09AA02
ENALADEX
Enaladex®|Vasotec®
Enalapril
Enalapril Bp
Enalapril maleate
Enalapril Richet
Enalaprila
|
Enalaprila [INN-Spanish]
Enalaprilat
Enalaprilum
Enalaprilum [INN-Latin]
EPL753
Gadopril
Kinfil
LEXXEL
Maleate, enalapril
Renitec
Renitek
VASERETIC
VASOTEC
Vasotec IV
|
|
5 |
|
Probucol |
Approved, Investigational |
Phase 4 |
|
23288-49-5 |
4912 |
Synonyms:
4,4'- (ISOPROPYLIDENEDITHIO)BIS(2,6-DI-TERT-BUTYLPHENOL)
4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]
Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Almirall brand OF probucol
Aventis brand OF probucol
Biphenabid
Bisbid
Bisphenabid
DH-581
|
DH-581|Lorelco®
Hoechst brand OF probucol
Lesterol
Lorelco
Lurselle
NSC-652160
NSC-86225
Panavir
PROBUCOL
Probucolum
Serterol
SINLESTAL
Superlipid
|
|
6 |
|
Bortezomib |
Approved, Investigational |
Phase 4 |
|
179324-69-7 |
387447 93860 |
Synonyms:
[(1R)-3-METHYL-1-({(2S)-3-PHENYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]PROPANOYL}AMINO)BUTYL]BORONIC ACID
341, PS
BORTEZOMIB
BORTEZOMIB HYDRATE
LDP 341
LDP-341
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
|
NSC-681239
PEPTIDE BORONATE
peptide boronate|PS-341|Velcade®
PS 341
PS-341
Velcade
|
|
7 |
|
Hydroxychloroquine |
Approved |
Phase 4 |
|
118-42-3 |
3652 |
Synonyms:
(+-)-Hydroxychloroquine
(±)-HYDROXYCHLOROQUINE
2-((4-((7-Chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
7-Chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-b-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinoline
7-Chloro-4-[4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[4-(N-ethyl-N-b-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino]quinoline
7-Chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
Axemal
DOLQUINE
Dolquine®|Plaquenil®
Ercoquin
Gen-Hydroxychloroquine 200mg Tablets
HCQ
Hidroxicloroquina
|
Hidroxicloroquina [inn-spanish]
Hydroxychlorochin
Hydroxychloroguine
HYDROXYCHLOROQUINE
Hydroxychloroquine sulfate
Hydroxychloroquine sulfate (1:1) salt
Hydroxychloroquinum
Hydroxychloroquinum [inn-latin]
Idrossiclorochina [dcit]
NSC4375
Oxichlorochine
Oxichlorochinum
Oxichloroquine
Oxychlorochin
Oxychloroquine
Plaquenil
Polirreumin
Quensyl
|
|
8 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 4 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
9 |
|
Rituximab |
Approved |
Phase 4 |
|
174722-31-7 |
|
Synonyms:
ABP-798
ANTICD20
CT-P10
HS006
HS-006
HS-006 (RITUXIMAB BIOSIMILAR)
HSDB 7455|IDEC-C2B8|MabThera®|Rituxan®
IDEC-102
IDEC-C2B8
IG GAMMA-1 CHAIN C REGION
Ig gamma-2A chain C region, membrane-bound form
MABTHERA
MABTHERA RITUXAN
|
R-105 IDEC-102
radiolabeled murine anti-CD20
RG-105
RHCACD20MA
RITUXAN
RITUXIMAB
rituximab-abbs
rituximab-arrx
rituximab-pvvr
SAIT101
SAIT-101
Zevalin
|
|
10 |
|
Losartan |
Approved |
Phase 4 |
|
114798-26-4 |
3961 |
Synonyms:
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
[<sup>3</sup>H]-losartan
2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
Cozaar
Cozaar®|DuP 753|MK-954
DuP 753
DUP 89
DuP-753
HGP1405
HGP-1405
|
Hyzaar
Lortaan
LOSARTAN
Losartan monopotassium salt
Losartan potassium
Losartic
MK-954
Monopotassium salt, losartan
Potassium, losartan
Salt, losartan monopotassium
|
|
11 |
|
Ramipril |
Approved |
Phase 4 |
|
87333-19-5 |
5362129 |
Synonyms:
(2S-(1(R*(r*)),2a,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate
(2S-(1(R*(r*)),2a,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
(2S-(1(R*(r*)),2α,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate
(2S-(1(R*(r*)),2α,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Acovil
Almirall brand OF ramipril
Altace
ALTACE (TN)
Altace®|HOE-498|Tritace®
Astra brand OF ramipril
AstraZeneca brand OF ramipril
Aventis brand OF ramipril
Aventis pharma brand OF ramipril
C09AA05
Carasel
Cardace
Delix
HOE 498
HOE-498
|
Hoechst brand OF ramipril
Hypren
Hytren
LOPACE
Lostapres
Monarch brand OF ramipril
Pramace
Promed brand OF ramipril
Quark
Ramace
RAMICOR
RAMIPRIL
Ramiprilum
Ramiprilum [Latin]
RANACE
Triatec
Tritace
Unipril
Vesdil
Zabien
|
|
12 |
|
Canagliflozin |
Approved |
Phase 4 |
|
842133-18-0 |
74323022 24812758 |
Synonyms:
1-(GLUCOPYRANOSYL)-4-METHYL-3-(5-(4-FLUOROPHENYL)-2-THIENYLMETHYL)BENZENE
CANAGLIFLOZIN
CANAGLIFLOZIN ANHYDROUS
Canagliflozina
Invokana®|JNJ-28431754|TA-7284
|
JNJ-24831754-ZAE
JNJ-28431754
JNJ-28431754-AAA
TA-7284
|
|
13 |
|
Dapagliflozin |
Approved |
Phase 4 |
|
461432-26-8 |
9887712 |
Synonyms:
(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
BMS-512148
BMS-512148|Farxiga®|Forxiga®
BMS-512148-05
|
Dapagliflozin
Dapagliflozina
FARXIGA
FORXIGA
|
|
14 |
|
Lisinopril |
Approved, Investigational |
Phase 4 |
|
83915-83-7, 76547-98-3 |
5362119 |
Synonyms:
(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
[N2-[(S)-1-CARBOXY-3-phenylpropyl]-L-lysyl-L-proline
Acerbon
Acercomp
Alapril
Carace
Cipral
Cipril
Coric
Inhibril
Inopril
Linopril
Linvas
Lipril
Lisinal
LISINOPRIL
Lisinopril anhydrous
LISINOPRIL DIHYDRATE
LISINOPRIL HYDRATE
Lisinopril maleate (1:1)
Lisinopril sulfate (1:2)
Lisinoprilum
Lisipril
|
Lisoril
Lispril
Loril
LPR
Lysinopril
MK-521
Noperten
Novatec
Presiten
Prinil
Prinivil
Prinivil®|Zestril®
Prinzide
Renacor
Sinopril
Sinopryl
Tensopril
Tensyn
Tersif
Vivatec
Zestoretic
Zestril
|
|
15 |
|
Empagliflozin |
Approved |
Phase 4 |
|
864070-44-0 |
73151030 11949646 |
Synonyms:
(1S)-1,5-ANHYDRO-1-(4-CHLORO-3-{4-[(3S)-TETRAHYDROFURAN-3-YLOXY]BENZYL}PHENYL)-D-GLUCITOL
(1S)-1,5-ANHYDRO-1-C-{4-CHLORO-3-((4-{((3S)-OXOLAN-3-YL)OXY}PHENYL)METHYL)PHENYL}-D-GLUCITOL
1-CHLORO-4-(GLUCOPYRANOS-1-YL)-2-(4-(TETRAHYDROFURAN-3-YLOXY)BENZYL)BENZENE
BI 10773
BI 10773|Jardiance®
BI10773
|
BI-10773
EMPAGLIFLOZIN
Empagliflozina
Empagliflozine
Empagliflozinum
JARDIANCE
|
|
16 |
|
Azathioprine |
Approved |
Phase 4 |
|
446-86-6 |
2265 |
Synonyms:
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
Azamun
AZAMUNE
Azanin
AZAPRESS
Azasan
Azathioprin
AZATHIOPRINE
Azathioprine sodium
Azathioprine sodium salt
Azathioprine sulfate
Azathioprinum
Azatioprin
Azatioprina
|
Azothioprine
BERKAPRINE
BW-57-322
Ccucol
IMMUNOPRIN 50
Immuran
Imuran
IMURAN (TN)
Imurek
Imurel
KENTAPRINE
Muran
NSC-39084
OPRISINE 50
Sodium, azathioprine
|
|
17 |
|
Valsartan |
Approved, Investigational |
Phase 4 |
|
137862-53-4 |
60846 |
Synonyms:
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
CGP-48933
CGP-48933|Diovan®|Prexxartan® (oral solution)
Diovan
EXFORGE
Kalpress
Miten
N-(p-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Nisis
|
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
PREXXARTAN
Provas
Tareg
VAL489
Vals
VALSARTAN
|
|
18 |
|
Angiotensin II |
Approved, Investigational |
Phase 4 |
|
68521-88-0, 11128-99-7, 4474-91-3 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
Angiotensin-(1-8) octapeptide
Angiotonin
|
Asp-arg-val-tyr-ile-his-pro-phe
Delivert
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-Α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
19 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 4 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
20 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 4 |
|
52-21-1 |
|
Synonyms:
ECONOPRED
FLO-PRED
METICORTELONE
NSC-10966
OMNIPRED
PRED FORTE
|
PRED FTE
PRED MILD
PREDNISOLONE 21-ACETATE
PREDNISOLONE ACETATE
STERANE
ULTRACORTENOL
|
|
21 |
|
Prednisolone |
Approved, Vet_approved |
Phase 4 |
|
50-24-8 |
4894 5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11Î’)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
3,20-Dioxo-11b,17a,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene
3,20-Dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Codelcortone
Co-Hydeltra
Cordrol
CORTALONE
Cotogesic
Cotolone
Decaprednil
Decortin H
DEKOTIL
Delcortol
Delta F
Delta(1)-Dehydrocortisol
Delta(1)-Dehydrohydrocortisone
Delta(1)-Hydrocortisone
DELTA.1-CORTISOL
DELTA.1-Cortisol|Orapred®|Pediapred®
Delta-Cortef
Deltacortenol
DELTACORTRIL
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
Deltahydrocortisone
DELTALONE
Deltasolone
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
DESOWEN
Dexa-Cortidelt Hostacortin H
Di adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Dicortol
DILACORT
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
FERNISOLONE-P
Flamasone
Hostacortin H
HYDELTRA
Hydeltrasol
HYDELTRA-TBA
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
IMS904
Inflamase Forte
Inflamase Mild
I-Pred
Key-Pred
Klismacort
Lentosone
Lite Pred
Medrol
|
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
METICORTELONE
METI-DERM
Metreton
M-Predrol
NEO-DELTA-CORTEF
Nisolone
Nor-Pred T.B.A.
NSC-9120
NSC-9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
ORAPRED
Panafcortelone
Paracortol
Paracotol
PEDIAPRED
PEVANTI
POLY-PRED
PRDL
Precortalon
Precortancyl
Precortilon
PRECORTISYL
PRECORTISYL FTE
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
PREDL
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone acetate
Prednisolone sodium phosphate
Prednisolone tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
PRELONE
Prenolone
Rolisone
SCHERIPROCT
Scherisolon
SERVISONE
Solone
Steran
STERANE
Sterolone
Supercortisol
TRIDESILON
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
VERDESO
Δ(1)-dehydrocortisol
Δ(1)-dehydrohydrocortisone
Δ(1)-hydrocortisone
Δ-cortef
|
|
22 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 4 |
|
2921-57-5 |
1875 |
Synonyms:
Methylprednisolone hemisuccinate
Methylprednisolone hemisuccinic acid
|
Methylprednisolone hydrogen succinate
Methylprednisolone succinate
|
|
23 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 4 |
|
83-43-2 |
4159 6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6Α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
1-Dehydro-6alpha-methylhydrocortisone
1-Dehydro-6a-methylhydrocortisone
1-Dehydro-6α-methylhydrocortisone
6 Methylprednisolone
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6a-Methylprednisolone
6-Methylprednisolone
6Α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
6Α-methylprednisolone
Artisone-Wyeth
Besonia
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
Dopomedrol
Esametone
Firmacort
J3.872E
Lemod
Medesone
Medixon
Medlone 21
Medrate
Medric acid
Medrol
Medrol Adt Pak
Medrol Dosepak
Medrol®|U-67590A
Medrone
Mesopren
|
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
Nirypan
Noretona
NSC-19987
Predni N Tablinen
Promacortine
Reactenol
Sieropresol
Solomet
SOLU-MEDROL
Summicort
Suprametil
U-67590A
Urbason
Urbasone
Wyacort
Δ(1)-6a-methylhydrocortisone
Δ(1)-6α-methylhydrocortisone
|
|
24 |
|
Basiliximab |
Approved, Investigational |
Phase 4 |
|
179045-86-4 |
|
Synonyms:
BASILIXIMAB
CHI621
CHI-621
CHI-621|L04AC02|SDZ-CHI-621|Simulect®
|
CHIMERIC MOUSE-HUMAN ANTICD25
IG GAMMA-1 CHAIN C REGION
SDZ-CHI-621
SIMULECT
|
|
25 |
|
Calcitriol |
Approved, Nutraceutical |
Phase 4 |
|
32222-06-3 |
5280453 |
Synonyms:
(1a,3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(1R,3S,5Z)-5-{2-[(1R,3AS,4E,7AR)-1-[(2R)-6-HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXANE-1,3-DIOL
(1S,3R,5Z,7E)-9,10-Seco-5,7,10(19)-cholestatriene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol
(1Α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
1 alpha, 25 Dihydroxy 20 epi vitamin D3
1 alpha, 25-Dihydroxy-20-epi-vitamin D3
1 alpha,25 Dihydroxycholecalciferol
1 alpha,25 Dihydroxyvitamin D3
1 alpha,25-Dihydroxycholecalciferol
1 alpha,25-Dihydroxyvitamin D3
1,25 Dihydroxy 20 epi vitamin D3
1,25 Dihydroxycholecalciferol
1,25 Dihydroxyvitamin D3
1,25(OH)2-20EPi-D3
1,25-DHCC
1,25-Dihydroxy-20-epi-vitamin D3
1,25-Dihydroxycholecalciferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1a,25(OH)2D3
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1a,25-Dihydroxyvitamin D3 / 1a,25-dihydroxycholecalciferol / calcitriol
1-a-25-Dihydroxyvitamin D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1Α,25(OH)2D3
1Α,25-dihydroxycholecalciferol
1Α,25-dihydroxyvitamin D3
1Α,25-dihydroxyvitamin D3 / 1α,25-dihydroxycholecalciferol / calcitriol
1-Α-25-dihydroxyvitamin D3
20 Epi 1alpha,25 dihydroxycholecaliferol
20-Epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
Abbott brand OF calcitriol
alpha,25-Dihydroxyvitamin D3, 1
Alphapharm brand OF calcitriol
Bocatriol
Calcijex
Calcijex®|calcitriol|Rocaltrol®
|
Calcitriol
Calcitriol abbott brand
Calcitriol alphapharm brand
Calcitriol cryopharma brand
Calcitriol galderma brand
Calcitriol gry brand
Calcitriol jenapharm brand
Calcitriol kyramed
Calcitriol kyramed brand
Calcitriol leo brand
Calcitriol medice brand
Calcitriol nefro
Calcitriol renacare brand
Calcitriol roche brand
Calcitriol-nefro
CalcitriolNefro
Calcitriolum
Cryopharma brand OF calcitriol
D3, 1 alpha,25-Dihydroxyvitamin
D3, 1,25-Dihydroxy-20-epi-vitamin
D3, 1,25-Dihydroxyvitamin
Decostriol
DIHYDROXYCHOLECALCIFEROL
DIHYDROXYVITAMIN D 3
Dihydroxyvitamin D3
Galderma brand OF calcitriol
Gry brand OF calcitriol
Hoffmann la roche brand OF calcitriol
Hoffmann-la roche brand OF calcitriol
Jenapharm brand OF calcitriol
KyraMed brand OF calcitriol
KyraMed, calcitriol
Leo brand OF calcitriol
Medice brand OF calcitriol
Osteotriol
RenaCare brand OF calcitriol
Renatriol
Ro 21-5535
RO-215535
RO-21-5535
Rocaltrol
Roche brand OF calcitriol
Silkis
Sitriol
Soltriol
Tirocal
Topitriol
Toptriol
VECTICAL
|
|
26 |
|
N,N-dimethylarginine |
Experimental |
Phase 4 |
|
30315-93-6 |
123831 |
Synonyms:
2-Amino-5-(amino-dimethylamino-methylidene)amino-pentanoate
2-Amino-5-(amino-dimethylamino-methylidene)amino-pentanoic acid
ADMA
Asymmetric dimethylarginine
Dimethyl-L-arginine
Guanidino-N,N-dimethylarginine
L-NG,NG-dimethylarginine
N(5)-((Dimethylamino)iminomethyl)-L-ornithine
N(g),N(g)-Dimethylarginine
|
N(g)-Dimethylarginine
N(g1),N(g1)-Dimethylarginine
N(Omega),N(omega)-dimethyl-L-arginine
N,N-Dimethylarginine
NG,NG-Dimethylarginine
NG,NG-Dimethyl-L-arginine
NG-Dimethylarginine
Nomega,nomega'-dimethyl-L-arginine
Nomega,nomega-dimethyl-L-arginine
|
|
27 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 4 |
|
2920-86-7 |
4897 |
Synonyms:
(+)-prednisolone hemisuccinate
4-(2-{14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-3,6-dien-14-yl}-2-oxoethoxy)-4-oxobutanoate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
PREDNISOLONE HEMISUCCINATE
Prednisolone hemisuccinic acid
Prednisolone hydrogen succinate
PREDNISOLONE SUCCINATE
|
|
28 |
|
Dexchlorpheniramine |
Experimental, Investigational |
Phase 4 |
|
25523-97-1 |
33036 |
Synonyms:
(+)-Chlorpheniramine
(S)-(+)-2-[p-Chloro-a-[2-(dimethylamino)ethyl]benzyl]pyridine
(S)-(+)-2-[p-Chloro-alpha-[2-(dimethylamino)ethyl]benzyl]pyridine
(S)-(+)-2-[p-Chloro-α-[2-(dimethylamino)ethyl]benzyl]pyridine
(S)-g-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine
(S)-gamma-(4-Chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine
(S)-Γ-(4-chlorophenyl)-N,N-dimethyl-2-pyridinepropanamine
chlorphenamine
Dapriton
D-Chloropheniramine
D-Chlorpheniramine
Dexchlorpheniramine
Dexchlorpheniramine maleate
Dexchlorpheniramine maleate (1:1), (+-)-isomer
Dexchlorpheniramine maleate (1:1), (R)-isomer
|
Dexchlorpheniramine maleate (1:1), (S)-isomer
Dexchlorpheniramine monohydrochloride
Dexchlorpheniramine sodium maleate (1:1)
Dexchlorpheniramine, (+-)-isomer
Dexchlorpheniramine, (R)-isomer
Dexchlorpheniramine, monohydrochloride, (S)-isomer
Dexchlorpheniraminum
Dexclor
Dexclorfeniramina
Dexclorfeniramine
Dextrochlorpheniramine maleate
Polaramin
Polaramine
Polargen TD
Polaronil
|
|
29 |
|
Mitogens |
|
Phase 4 |
|
|
|
30 |
|
interferons |
|
Phase 4 |
|
|
|
31 |
|
Interferon-alpha |
|
Phase 4 |
|
|
|
32 |
|
Cassava |
|
Phase 4 |
|
|
|
33 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
34 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
35 |
|
Anticholesteremic Agents |
|
Phase 4 |
|
|
|
36 |
|
Omega 3 Fatty Acid |
|
Phase 4 |
|
|
|
37 |
|
Vitamins |
|
Phase 4 |
|
|
|
38 |
|
Trace Elements |
|
Phase 4 |
|
|
|
39 |
|
Vasoconstrictor Agents |
|
Phase 4 |
|
|
|
40 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
41 |
|
Micronutrients |
|
Phase 4 |
|
|
|
42 |
|
Antiprotozoal Agents |
|
Phase 4 |
|
|
|
43 |
|
Antiparasitic Agents |
|
Phase 4 |
|
|
|
44 |
|
Antimalarials |
|
Phase 4 |
|
|
|
45 |
|
Proteasome Inhibitors |
|
Phase 4 |
|
|
|
46 |
|
Angiotensin-Converting Enzyme Inhibitors |
|
Phase 4 |
|
|
|
47 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
48 |
|
Antiemetics |
|
Phase 4 |
|
|
|
49 |
|
Immunosuppressive Agents |
|
Phase 4 |
|
|
|
50 |
|
Alkylating Agents |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 277)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency |
Unknown status |
NCT04020328 |
Phase 4 |
Leflunomide 20 mg+prednisone 0.5mg/kg/d |
2 |
A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy |
Unknown status |
NCT01184599 |
Phase 4 |
aliskiren |
3 |
Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis-a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial |
Unknown status |
NCT02063100 |
Phase 4 |
Shenyankangfu tablets;Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 50mg;Shenyankangfu tablets and Losartan potassium 100mg;Losartan potassium 100mg |
4 |
The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis : A Multicenter, Prospective, Randomized, Controlled, Single-blind Trial. |
Unknown status |
NCT03062813 |
Phase 4 |
Tacrolimus &entecavir;placebo & entecavir |
5 |
Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis:A Multicenter Randomized Controlled Clinical Trial |
Unknown status |
NCT04349683 |
Phase 4 |
Jinshuibao;Placebo |
6 |
Calcitriol in the Treatment of Immunoglobulin A Nephropathy |
Unknown status |
NCT00862693 |
Phase 4 |
Calcitriol |
7 |
Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy |
Unknown status |
NCT02981212 |
Phase 4 |
Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB |
8 |
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study |
Unknown status |
NCT02765594 |
Phase 4 |
Hydroxychloroquine Sulfate;Valsartan |
9 |
A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology |
Unknown status |
NCT02571842 |
Phase 4 |
Intravenous Rituximab;ACEI/ARB and corticosteroids |
10 |
An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy |
Unknown status |
NCT03218852 |
Phase 4 |
prednisone and cyclophosphamide;prednisone alone |
11 |
A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy |
Unknown status |
NCT03170323 |
Phase 4 |
Mycophenolate Mofetil;Cyclosporins |
12 |
A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy |
Unknown status |
NCT01758120 |
Phase 4 |
prednisone plus cyclophosphamide;Prednisone alone |
13 |
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial |
Unknown status |
NCT02231125 |
Phase 4 |
Losartan;Abelmoschus manihot |
14 |
Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) |
Completed |
NCT00843856 |
Phase 4 |
tacrolimus;tacrolimus and mycophenolate mofetil |
15 |
A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy |
Completed |
NCT00426348 |
Phase 4 |
Valsartan;Probucol;Placebo |
16 |
Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis |
Completed |
NCT01115426 |
Phase 4 |
Ramipril or losartan |
17 |
HSP-glomerulonephritis Trial: MP vs CyA |
Completed |
NCT00425724 |
Phase 4 |
Methylprednisolone pulses plus prednisone versus Cyclosporine A |
18 |
A Prospective, Randomized, Open Label, Case-Controlled Study on the Efficacy of Mycophenolate Mofetil for IgA Nephropathy Patients With Heavy Proteinuria Despite Angiotensin Blockade |
Completed |
NCT00863252 |
Phase 4 |
mycophenolate mofetil;angiotensin blockade |
19 |
A Multicenter, Randomized, Prospective, Open-Label Trial of Rituximab in the Treatment of Progressive IgA Nephropathy |
Completed |
NCT00498368 |
Phase 4 |
Intravenous Rituximab;ACE/ARB |
20 |
Corticosteroids and Azathioprine Versus Corticosteroids Alone in IgA Nephropathy: a Randomized Controlled Trial. |
Completed |
NCT00755859 |
Phase 4 |
steroids plus azathioprine;steroids |
21 |
Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy |
Completed |
NCT03025828 |
Phase 4 |
ACTHar |
22 |
To Compare the Efficacy and Safety of TW vs Valsartan in the MN |
Completed |
NCT00518219 |
Phase 4 |
TW |
23 |
Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease |
Completed |
NCT02351752 |
Phase 4 |
Hydroxychloroquine Sulfate |
24 |
Multitarget Therapy for Idiopathic Membranous Nephropathy |
Completed |
NCT04424862 |
Phase 4 |
Prednisone, ciclosporin and mycophenolate mofetil;Ponticelli Regimen |
25 |
Velcade Therapy for Severe IgA Nephropathy |
Completed |
NCT01103778 |
Phase 4 |
Bortezomib (Velcade®) |
26 |
Aliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot Study |
Completed |
NCT00922311 |
Phase 4 |
Aliskiren |
27 |
The Safety and Short-Term Efficacy of Calcitriol in the Treatment of Immunoglobulin A Nephropathy |
Completed |
NCT00319761 |
Phase 4 |
Calcitriol |
28 |
Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy |
Completed |
NCT00367562 |
Phase 4 |
ENALAPRIL VALSARTAN METHYLPREDNISONE |
29 |
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) |
Completed |
NCT01386554 |
Phase 4 |
Repository Corticotropin Injection;Placebo |
30 |
Huaiqihuang Granule in CKD Stage 3 Primary Glomerulonephritis: A Multicentre Prospective, Randomized, Double-blind and Imitation, Positive-drug Parallel Controlled Clinical Trail |
Recruiting |
NCT04263922 |
Phase 4 |
Huaiqihuang granules;Valsartan capsule |
31 |
A Multicentre, Randomized, Controlled Study of Rituximab in Treatment of Primary IgA Nephropathy |
Recruiting |
NCT04525729 |
Phase 4 |
Rituximab;RAS 2410 |
32 |
A Multicenter, Comparative Safety and Efficacy Study of ACTHar Gel Alone or in Combination With Oral Tacrolimus to Reduce Urinary Proteinuria in Patients With Idiopathic DNAJB9 Positive Fibrillary Glomerulopathy |
Active, not recruiting |
NCT05546047 |
Phase 4 |
Acthar Gel 80 UNT/ML Injectable Solution |
33 |
Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. |
Not yet recruiting |
NCT04662723 |
Phase 4 |
Corticosteroid;Renin-angiotensin sytem blockers;Sodium-glucose cotransporter 2 inhibitor |
34 |
Clinical Study of Rituximab or Cyclophosphamide Combined With Steroids in the Treatment of Idiopathic Membranous Nephropathy |
Not yet recruiting |
NCT05514015 |
Phase 4 |
Rituximab;Cyclophosphamide |
35 |
Effect of Immunosuppression in IgA Nephropathy |
Not yet recruiting |
NCT03468972 |
Phase 4 |
Immunosuppressive treatment |
36 |
Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease |
Terminated |
NCT01129557 |
Phase 4 |
Aliskiren;Valsartan |
37 |
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment |
Terminated |
NCT02523768 |
Phase 4 |
ATG-F;Simulect |
38 |
An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis |
Withdrawn |
NCT01926054 |
Phase 4 |
Acthar gel |
39 |
Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria |
Withdrawn |
NCT02382523 |
Phase 4 |
Acthar 80 unit injection |
40 |
A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy |
Unknown status |
NCT03018535 |
Phase 3 |
Rituximab;Methylprednisolone;Cyclophosphamide |
41 |
Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis |
Unknown status |
NCT03180723 |
Phase 3 |
Rituximab;Cyclosporin |
42 |
A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy |
Unknown status |
NCT01282073 |
Phase 3 |
Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid |
43 |
A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients |
Unknown status |
NCT03357653 |
Phase 3 |
Losartan group;Placebo group |
44 |
Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy -- A Prospective, Randomized, Controlled, Multi-Center Clinical Trial |
Unknown status |
NCT02662283 |
Phase 2, Phase 3 |
Prednisolone;Reh-acteoside |
45 |
Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f |
Unknown status |
NCT02187900 |
Phase 3 |
Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH);Mycophenolate mofetil (MMF) |
46 |
A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) |
Completed |
NCT00404833 |
Phase 3 |
prednisolone and mycophenolate mofetil;prednisolone and chlorambucil |
47 |
A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membranous Nephritis |
Completed |
NCT00404794 |
Phase 3 |
prednisolone and mycophenolate mofetil;prednisolone and tacrolimus |
48 |
Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy |
Completed |
NCT00135954 |
Phase 3 |
Cyclophosphamide and steroids |
49 |
Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study |
Completed |
NCT00135967 |
Phase 2, Phase 3 |
mycophenolate mofetil orally 1000 mg twice a day (BID);prednisone 0,5 mg/kg orally on alternate days;intravenous (i.v.) methylprednisolone 1000 mg, total 9 |
50 |
A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy |
Completed |
NCT02232776 |
Phase 3 |
Losartan |
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Glomerulonephritis:
Embryonic/Adult Cultured Cells Related to Glomerulonephritis:
|